Cancer is the second leading cause of death in New York State, which has one of the highest cancer rates in the country. More than 100,000 New Yorkers will be diagnosed with some type of cancer this year.

Even if tumors are detected after they become cancerous, colorectal cancer is still very treatable and slow to develop. Patients can take some time to decide which treatments are best for their situation and shouldn’t feel like they need to rush into an immediate treatment decision.

In the 1950s, nothing much could be done for patients with acute lymphoblastic leukemia (ALL). Dr. Jim Holland was determined to change that.

“It’s so important to have conversations with patients when they do have a life-limiting illness. It is the only way to ensure that patients and their families are prepared and that their wishes regarding end-of-life care are honored.”

On January 29, the Food and Drug Administration approved a lutetium Lu 177 dotatate (Lutathera^®), a targeted radiation drug, for the treatment of gastroenteropancreatic neuroendocrine tumors.